November 27, 2024November 27, 2024 Shilpa Medicare, in partnership with the Zydus Group through their joint venture Oncosol, and its collaborator Shorla Oncology, announced on November 27 that the USFDA has approved IMKELDI, the first oral liquid form of imatinib for treating certain types of…
October 18, 2024October 18, 2024 Shares of Zydus Lifesciences were trading in the green and 1% higher on 18 October after the company received approval from the US Food and Drug Administration (USFDA) to manufacture Fludrocortisone Acetate Tablets USP, 0.1 mg. The Fludrocortisone Acetate Tablets USP, 0.1 mg, are…
October 11, 2024October 11, 2024 Shares of Zydus Lifesciences Ltd. ended flat after hitting a day’s high of Rs 1,070.50 on 11th October, despite the firm announcing yesterday that it has received final approval from the United States Food and Drug Administration (USFDA) to manufacture paliperidone extended-release tablets in…
October 1, 2024October 1, 2024 Shares of Zydus Lifesciences were trading higher by 1% on 1 October after the company announced that it had received an ‘Establishment Inspection Report (EIR)’ from the USFDA (United States Food and Drug Administration). The US health regulator conducted an inspection at the company’s…
Shares of Zydus Lifesciences Ltd were trading 3% lower on 22 May despite the company receiving final approval from the US health authorities to produce and sell 300 mg and 450 mg doses of Theophylline Extended-Release Tablets. The business informed the stock exchanges that the tablets can be used to treat COPD, also known as chronic…